Verici Dx Plc Cash Flow Conversion Efficiency
Verici Dx Plc cash flow conversion efficiency. Based on the latest financial reports, Verici Dx Plc (VRCI) has a cash flow conversion efficiency ratio of -1.091x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.71 Million ≈ $-329.35 USD) by net assets (GBX2.48 Million ≈ $301.99 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Verici Dx Plc (2020–2024)
Cash flow conversion efficiency of Verici Dx Plc from 2020 to 2024. This chart illustrates how Verici Dx Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Verici Dx Plc (VRCI) stock price for real-time trading data and today's change.
Verici Dx Plc Cash Flow Conversion Ratio Explained
Verici Dx Plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Verici Dx Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verici Dx Plc ranked by their cash flow conversion efficiency. Also see Verici Dx Plc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quantum Blockchain Technologies Plc
LSE:QBT
|
0.209x |
|
GREENHAWK RESOURCES INC.
F:2V70
|
-1.279x |
|
Oneiro Energy PLC
LSE:ONE
|
N/A |
|
BP PLC
F:BPE
|
0.103x |
|
Indus Gas Limited
LSE:INDI
|
0.006x |
|
Novae Group Plc
STU:NVAL
|
0.085x |
|
Presto Automation Inc.
NASDAQ:PRST
|
0.176x |
|
London & Associated Properties
LSE:LAS
|
0.063x |
Annual Cash Flow Conversion Efficiency for Verici Dx Plc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Verici Dx Plc from 2020 to 2024. Review Verici Dx Plc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX5.26 Million ≈ $640.60 |
GBX-6.02 Million ≈ $-732.46 |
-1.143x | +43.18% |
| 2023-12-31 | GBX3.56 Million ≈ $432.91 |
GBX-7.16 Million ≈ $-871.16 |
-2.012x | -130.04% |
| 2022-12-31 | GBX11.51 Million ≈ $1.40K |
GBX-10.07 Million ≈ $-1.22K |
-0.875x | -65.46% |
| 2021-12-31 | GBX11.98 Million ≈ $1.46K |
GBX-6.34 Million ≈ $-770.96 |
-0.529x | -709.63% |
| 2020-12-31 | GBX19.62 Million ≈ $2.39K |
GBX-1.28 Million ≈ $-155.92 |
-0.065x | -- |
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more